Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Final hours: unlock premium data with Claim 60% OFF
Close

Roche Holding AG (RO)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
247.60 0.00    0.00%
28/06 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  CH0012032113 
S/N:  851311
  • Volume: 0
  • Bid/Ask: 246.40 / 247.80
  • Day's Range: 244.40 - 247.60
Roche Holding 247.60 0.00 0.00%

SIX:RO Financials

 
A brief overview of the SIX:RO financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Roche Holding AG over time.

Roche Holding AG reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CHF 29,779 million compared to CHF 32,295 million a year ago. Revenue was CHF 30,616 million compared to CHF 33,900 million a year ago. Net income was CHF 7,137 million compared to CHF 8,530 million a year ago. Basic earnings per share from continuing operations was CHF 8.93 compared to CHF 10.65 a year ago. Diluted earnings per share from continuing operations was CHF 8.87 compared to CHF 10.54 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

RO Income Statement

Gross margin TTM 73.12%
Operating margin TTM 30.66%
Net Profit margin TTM 21.15%
Return on Investment TTM 28.17%
 Total Revenue  Net Income
Period Ending: Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022
Total Revenue 15308 15308 16094 16094
Gross Profit 11498.5 11498.5 11577 11577
Operating Income 5326 5326 4503.5 4503.5
Net Income 3568.5 3568.5 1945.5 1945.5

RO Balance Sheet

Quick Ratio MRQ 0.78
Current Ratio MRQ 1.18
LT Debt to Equity MRQ 29.84%
Total Debt to Equity MRQ 42.94%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022
Total Assets 84370 84370 88151 88151
Total Liabilities 54026 54026 56136 56136
Total Equity 30344 30344 32015 32015

RO Cash Flow Statement

Cash Flow/Share TTM 26.19
Revenue/Share TTM 82.21
Operating Cash Flow  15.07%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 3949 3949 4453 4453
Cash From Investing Activities -241 -241 -2504.5 -2504.5
Cash From Financing Activities -4146.5 -4146.5 -1480 -1480
Net Change in Cash -635.5 -635.5 338 338
* In Millions of CHF (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

RO Comments

Write your thoughts about Roche Holding AG Frankfurt
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Reply
2 2
Report
Lee John
Lee John Nov 16, 2020 3:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
Reply
1 0
Report
Jonny Tr
Jonny Tr May 04, 2020 8:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Just like Biolidics. they get approval for Covid19 tests kits in USA
Reply
1 0
Report
Billy Hanafi
Billy Hanafi Jan 25, 2019 10:12AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i dont know
Reply
0 0
Report
edgard hajjar
edgard hajjar May 07, 2018 5:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
is the historical price adjusted for stock splits?
Reply
2 0
Report
Billy Hanafi
Billy Hanafi May 07, 2018 5:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i dont know
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email